Summary & Overview
HCPCS Level II J1130: Injection, diclofenac sodium, 0.5 mg
HCPCS Level II code J1130 denotes an injectable dose of diclofenac sodium at 0.5 mg per billing unit, used to record administration of an NSAID via parenteral route. Nationally, accurate reporting of injectable drug codes like J1130 matters for clinical documentation, pharmacy oversight, and payment integrity because injectable agents are high-cost items and are subject to specific coverage and billing rules across payers. Key payers considered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what J1130 represents, the typical service setting for its use, and which payers are commonly involved in coverage decisions. The publication also guides readers through policy and billing topics to expect in detailed sections: payer-specific coverage and reimbursement benchmarks, coding and billing nuances for injectable NSAIDs, and relevant clinical context for administration. Data not provided in the source input—such as associated taxonomies, ICD-10 diagnosis mapping, and related codes—is noted as unavailable and will be addressed where present in full analyses. This national-level summary is intended to orient billing managers, clinical coders, and policy analysts to the core function and reporting context of HCPCS Level II code J1130.
Billing Code Overview
HCPCS Level II code J1130 represents an injection of diclofenac sodium, with the billing unit defined as 0.5 mg. This code is used to report administration of a nonsteroidal anti-inflammatory drug (NSAID) in injectable form.
Service type: Injection / Parenteral Drug Administration
Typical site of service: Outpatient clinic, physician office, or ambulatory care setting
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with acute musculoskeletal pain localized to a joint or soft-tissue region (for example, a patient presenting with an acute flare of osteoarthritis of the knee or an exacerbation of lateral epicondylitis) who receives an intramuscular or periarticular injection of diclofenac sodium, J1130 (0.5 mg). The clinical workflow typically includes: initial evaluation by an orthopedist, pain-management specialist, primary care physician, or sports medicine clinician; confirmation of indication and allergy screen; explanation of risks and benefits and obtaining verbal or written consent per facility policy; preparation of the injection in a procedure area; performance of the injection using standard aseptic technique; and post‑injection monitoring for immediate adverse reaction for the time required by the site of service. Documentation includes indication, informed consent, medication name and dose (diclofenac sodium 0.5 mg), route and site of administration, lot number and expiration when applicable, any immediate response, and aftercare instructions. Typical sites of service are outpatient ambulatory clinics, physician office procedure rooms, urgent care centers, and outpatient hospital departments. Typical patient scenario: an adult with chronic knee osteoarthritis refractory to oral therapy who presents for targeted periarticular analgesia and receives a single J1130 injection with observation and return precautions documented.
Coding Specifications
| Modifier | Description | When to Use |
|---|